In a first-in-human study of 56 healthy volunteers, 42 received RPT1G with no treatment-emergent adverse events above Grade 2, no serious adverse events, and no discontinuations. Pharmacodynamic assays showed NAMPT target engagement at all dose levels, and the FDA has cleared an IND to begin a Phase 1 trial in relapsed/refractory AML and higher-risk MDS, authorizing an initial patient dose equal to the highest dose tested in volunteers. The program also secured orphan drug designation in AML.
The core development is a bid to revive the long-challenging NAMPT target with a small molecule designed for selective inhibition and improved tolerability. Remedy Plan’s sequencing—healthy volunteer SAD/MAD to lock in safety and PD, followed by an oncology Phase 1 starting at a higher, biologically informed dose—aims to shortcut the subtherapeutic patient escalations that have slowed and sometimes derailed prior NAMPT programs. The company plans to present the healthy volunteer dataset, patient trial design, and new preclinical lymphoma data at ASH on December 8.
Strategically, the package is notable for dose selection discipline and for leaning into the FDA’s dosing optimization agenda. The agency’s green light to open at the top healthy volunteer dose signals comfort with the exposure margins. It may reduce the number of patient cohorts needed to reach pharmacologically relevant levels. That matters in AML and HR-MDS, where the window to detect a signal is constrained by class-specific toxicities and prior NAMPT inhibitors. The claim of consistent target engagement across the healthy volunteer range is the operational hinge. If those PD levels translate in patients without lineage or ocular liabilities, the program could reframe the risk profile that has shadowed this enzyme.
For sites and CROs, the first-in-patient study will hinge on tight operational control of class-relevant safety domains and real-time PD sampling. Expect protocols to embed frequent labs, ophthalmologic assessments, and exposure–response analyses aligned with modern FDA expectations, plus central testing to confirm on-target activity in blasts. Competing for R/R AML and HR-MDS patients remains a headwind; sponsors that can demonstrate fast escalation to active doses and a clean early safety run-in tend to win site engagement. If RPT1G remains a monotherapy at entry, the logistics are simpler; however, the commercial path in AML increasingly runs through combinations, which adds design complexity, drug–drug interaction monitoring, and broader site coordination.
Regulators and payers will look for more than tolerability: durable blast reductions, translational PD–efficacy linkage, and clarity on dose intensity without frequent interruptions or reductions. The orphan designation shores up incentives but does not de-risk the clinical biology. For competing sponsors, the move underscores a broader development trend: front-loading PK/PD and target engagement outside oncology populations to justify higher initial patient dosing and to compress timelines to decision points.
What to watch next is whether the patient trial reproduces the PD seen in volunteers, the speed at which the study reaches exposures tied to target engagement, and any emergence of cytopenias, hepatic signals, or ocular effects at those levels. The ASH presentation should outline the dose-escalation schema, DLT definitions, biomarker plans, and whether the program is architected to enable a rapid pivot to combinations with hypomethylating agents or BCL2 inhibitors if monotherapy activity is modest. The immediate risk is translation: healthy volunteer safety does not guarantee tolerability in heavily pretreated AML, and the field will discount the program until an early efficacy signal and a defensible recommended Phase 2 dose are in hand.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
